Organization (Other)
Novan, Inc.
ClinicalTrials.gov lists Novan, Inc. as lead sponsor of 21 trials. It has 17 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Novan, Inc.: 21 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Acne Vulgaris | 13 |
| Molluscum Contagiosum | 4 |
| Condylomata Acuminata | 1 |
| Dermatitis, Atopic | 1 |
| Foot Dermatoses | 1 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 5 |
| 2015 | 2 |
| 2014 | 3 |
| 2013 | 2 |
| 2012 | 2 |
| 2011 | 1 |
Recruitment duration, a model prediction: none of the 21 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (17)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| SB204 4% | Acne Vulgaris | Phase 3 | 6 |
| Vehicle Gel | Acne Vulgaris | Phase 3 | 6 |
| SB206 12% | Molluscum Contagiosum | Phase 3 | 3 |
| SB206 10.3% berdazimer | Molluscum Contagiosum | Phase 3 | 1 |
| Vehicle Gel | Molluscum Contagiosum | Phase 3 | 1 |
Showing 5 of 17 active programs.
Approved assets (1)
| Drug | Trials |
|---|---|
| SB204 | 3 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 100% hit target (n=6) | 60% on time (n=5) |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American journal of clinical dermatology | 1 |
| JAMA dermatology | 1 |
| JID innovations : skin science from molecules to population health | 1 |
| The Journal of clinical and aesthetic dermatology | 1 |
| The Journal of investigative dermatology | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 38 | 7 | 2023-11-14 |
Financing and grant events (3)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2023-04-19 | SBIR award | 1 | Reporter |
| 2021-04-08 | SBIR award | 126,370 | Reporter |
| 2020-02-18 | SBIR award | 997,413 | Reporter |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| PPD Development, LP | Uses vendor | 1 |
| Premier Research | Uses vendor | 1 |
Latest dated events (62)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2023-11-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-08-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-04-19 | SBIR award | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2023-02-21 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2022-12-27 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 62 events.
Biomarker capability evidence (9)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| HRH2 | Trial sponsor | Named in trial exclusion criteria |
| HRH2 | Trial sponsor | Named in trial exclusion criteria |
| HRH2 | Trial sponsor | Named in trial exclusion criteria |
| HRH2 | Trial sponsor | Named in trial exclusion criteria |
| HRH2 | Trial sponsor | Mentioned in trial text |
Showing 5 of 9 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.